STOCK TITAN
  1. Home
  2. News
  3. BBIO

BridgeBio Pharma Inc - BBIO STOCK NEWS

Welcome to our dedicated news page for BridgeBio Pharma (Ticker: BBIO), a resource for investors and traders seeking the latest updates and insights on BridgeBio Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BridgeBio Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BridgeBio Pharma's position in the market.

News
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) presented additional Phase 3 data from ATTRibute-CM, its study of acoramidis in transthyretin amyloid cardiomyopathy, at the American Heart Association Scientific Sessions 2023. The study demonstrated that acoramidis improved clinical outcomes for ATTR-CM patients, showing early and sustained benefits on survival and cardiovascular-related hospitalization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
BridgeBio Pharma to Present Additional Data from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American Heart Association (AHA) Scientific Sessions 2023
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced additional Phase 3 data on clinical outcomes from ATTRibute-CM, its study of acoramidis in ATTR-CM, to be presented at the AHA Scientific Sessions 2023. The highly statistically significant result on the primary endpoint of ATTRibute-CM with a Win Ratio of 1.8 (p<0.0001) will be discussed at an investor call on November 12 at 11:15 am ET. Acoramidis, an investigational, next-generation, orally-administered, highly potent, small molecule stabilizer of transthyretin, showed improved clinical outcomes in Transthyretin Amyloid Cardiomyopathy Patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.89%
Tags
conferences clinical trial
-
News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced the grant of 183,533 restricted stock units to 33 new employees. The shares will vest over time, subject to continued employment. The awards were made under the Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
BridgeBio Pharma, Inc. presented positive results from the ATTRibute-CM Phase 3 study at the ESC Congress. The study showed that acoramidis improved patient survival and reduced hospitalizations. A New Drug Application for acoramidis is expected to be filed with the FDA by the end of 2023. BridgeBio also had positive regulatory meetings for infigratinib and reached alignment on a Phase 3 clinical trial. Other updates include data from Phase 2 trials and progress in KRAS programs. The company raised $316 million in gross proceeds and ended the third quarter with $522 million in cash.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
earnings
-
News
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BridgeBio Pharma grants restricted stock units to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
none
-
News
BridgeBio Pharma Announces New England Journal of Medicine Publication of Positive Encaleret Proof-of-Concept Phase 2b Results in Patients with Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Rhea-AI Summary
BridgeBio announces positive Phase 2b data for encaleret in patients with ADH1
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
clinical trial
News
BridgeBio Pharma Shares Positive Long-Term Data from an Ongoing Phase 2 Study, which Support the Potential Use of Glycosylated Alpha-dystroglycan (⍺DG) Levels as a Surrogate Endpoint in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Rhea-AI Summary
BridgeBio Pharma presents long-term data from Phase 2 trial in patients with LGMD2I/R9
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
clinical trial
-
News
BridgeBio and Resilience Announce Strategic Multi-Year Partnership to Advance BBP-631, BBP-812 and Future Gene Therapy Treatments
Rhea-AI Summary
BridgeBio Pharma and Resilience announce a strategic collaboration to manufacture and advance gene therapies for Canavan disease and congenital adrenal hyperplasia (CAH)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
partnership
-
News
BridgeBio Pharma Announces $250 Million Private Placement Equity Financing
Rhea-AI Summary
BridgeBio Pharma, Inc. has secured $250 million financing through a PIPE financing led by Qatar Investment Authority and four major US investment management firms. The raise is expected to fully capitalize the company to profitability. The gross proceeds from the financing are anticipated to be approximately $250 million. The financing is expected to close on September 27, 2023. The company will use the funds to support its future operations and pursue additional financing options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
News
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
BridgeBio Pharma grants restricted stock units to new employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
none
Stock BBIO logo
BridgeBio Pharma Inc

Nasdaq:BBIO

BBIO Rankings

#1491 Ranked by Market Cap
#87 Ranked by Stock Gains
N/A Ranked by Dividends

BBIO Stock Data

4.95B
113.02M
5.37%
92.11%
7.74%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Palo Alto

About BBIO

we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.